Stock SOLTF NXERA PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Nxera Pharma Co., Ltd. OTC Markets

Equities

SOLTF

JP3431300007

Market Closed - OTC Markets
Other stock markets
 17:20:04 20/06/2024 BST 		5-day change 1st Jan Change
9.43 USD -5.70% Intraday chart for Nxera Pharma Co., Ltd. 0.00% -5.70%
06-27 Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment MT
06-27 Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment
MT
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
AQ
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
CI
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
AQ
Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals
MT
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
AQ
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
AQ
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
CI
Nxera Pharma Co., Ltd. and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
CI
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
AQ
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
AQ
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
AQ
Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May
MT
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
AQ
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test
MT
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
AQ
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,
MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea
AQ
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4565 Stock
  4. SOLTF Stock
  5. News Nxera Pharma Co., Ltd.